热门资讯> 正文

Eikon Therapeutics，Inc. GAAP每股收益为-1.63美元，低于0.03美元

2026-08-14 04:59

Eikon Therapeutics(EIKN) 0
XMAX, Inc.(XMAX) 0

Eikon Therapeutics, Inc. press release (EIKN): Q2 GAAP EPS of -$1.63 misses by $0.03.
As of June 30, 2026, Eikon had cash, cash equivalents, and marketable securities of $531.2 million. Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the second half of 2027.

More on Eikon Therapeutics, Inc.

Eikon Therapeutics: Behind The Rough Debut
Eikon Therapeutics: Buy TLR Combinatory Potential Only After Lock-Up Expiry
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating
Historical earnings data for Eikon Therapeutics, Inc.
Financial information for Eikon Therapeutics, Inc.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。